Needham Upgrades Hims & Hers to Buy, Citing Improved Growth Trajectory

Needham & Company has upgraded Hims & Hers Holdings Inc. (HIMS) to Buy from Hold, marking a shift in analyst sentiment based on recent financial performance and strategic repositioning. The firm cited a 12% year-over-year increase in recurring revenue during the fourth quarter of fiscal 2025 as a key driver of the upgrade, signaling improved customer retention and monetization of its digital health platform. The upgrade follows HIMS' announcement of a 25% reduction in customer acquisition costs over the past 12 months, attributed to enhanced targeting algorithms and optimized marketing spend. This efficiency gain has contributed to a 4.7% improvement in adjusted EBITDA margin, reaching 18.3% in Q4 2025, up from 13.6% in the same period the prior year. HIMS reported total revenue of $237 million for the fourth quarter, exceeding the consensus estimate of $225 million. The company also expanded its product suite to include new mental health and dermatology offerings, which collectively accounted for 31% of new user sign-ups in Q4. The upgrade is expected to influence investor positioning, particularly among retail and growth-focused institutional investors. While the move is limited to a single stock within the healthcare sector, it may prompt renewed interest in digital health companies with scalable consumer models. HIMS shares rose 4.2% in early trading following the announcement, though the impact remains contained to the company’s market capitalization of approximately $1.8 billion.